(51 days)
The HEP-ANA Test System is an indirect fluorescent antibody assay utilizing HEp-2 tissue culture cells as a substrate for the qualitative and/or semi-quantitative determination of antinuclear antibodies in human serum. The HEP-ANA Test System is intended for use as an aid in the diagnosis of certain autoimument diseases.
The RhiGene HEP-ANA Test System is an indirect fluorescent antibody assay utilizing HEp-2 tissue culture cells as a substrate, similar to the predicate device. Diluted serum samples are incubated on substrate slides coated with HEP-2 (human epithelial) cells. Incubation allows the anti-nuclear antibodies (ANA) present in the samples to react with the antigen. After the removal of unbound serum proteins by washing, antibodies specific for human immunoglobulins, labeled with fluorescein isothiocyanate (FITC), are added forming complexes with the nuclear bound antibodies. Following another washing step, coverslips are mounted and then the slides are examined with a fluorescence microscope. The total incubation time (at room temperature in a moist chamber) of the assay is 40 minutes.
Here's an analysis of the provided text, outlining the acceptance criteria and study details for the RhiGene HEP-ANA Test System:
Acceptance Criteria and Device Performance
The core of the acceptance criteria is predicated on the new device, the RhiGene HEP-ANA Test System, demonstrating substantial equivalence to a legally marketed predicate device, the RhiGene Titer-Fluor ANA Test System (K872845). While explicit numerical acceptance targets aren't given in the summary, the study's goal was to show comparable performance.
The "reported device performance" refers to the RhiGene HEP-ANA Test System. It's compared directly to the predicate device, with results indicating equivalence rather than specific performance metrics in isolation.
| Acceptance Criterion (Implicit) | Reported Device Performance (RhiGene HEP-ANA Test System) | Predicate Device (RhiGene Titer-Fluor ANA Test System) |
|---|---|---|
| Clinical Specificity (Healthy Donor Serum) | 82% | 78% |
| Sensitivity (Autoimmune Diseases Population) | 75% | 75% |
| Overall Performance Characteristics | Comparable | Comparable |
Study Details
-
Sample Size used for the test set and the data provenance:
- Sample Size: Not explicitly stated as a single number.
- "a healthy donor serum population"
- "an autoimmune diseases population"
- Data Provenance: Not explicitly stated (e.g., country of origin). The studies were "In-house studies," implying they were conducted by RhiGene Inc. The samples appear retrospective as they are described as "populations" rather than detailing a prospective enrollment strategy.
- Sample Size: Not explicitly stated as a single number.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- This information is not provided in the summary. The ground truth for the healthy and autoimmune populations would have been established through clinical diagnosis, but the involvement of specific experts for validating these diagnoses for the study is not mentioned.
-
Adjudication method (e.g., 2+1, 3+1, none) for the test set:
- This information is not provided in the summary.
-
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- An MRMC study was not performed. This device is an in-vitro diagnostic (IVD) assay, not an AI-powered image analysis tool requiring human reader interpretation. The performance is based on the assay's output as interpreted by laboratory personnel.
-
If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
- A "standalone" study in the typical AI sense (algorithm only) was not performed as this is a traditional laboratory assay. However, the performance metrics (specificity and sensitivity) are representative of the device's inherent capability, with human involvement primarily in performing the assay and interpreting the fluorescent patterns, not the "algorithm" itself. The comparison is between two similar lab assays.
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- For specificity, the ground truth was derived from a "healthy donor serum population." This implies individuals diagnosed as healthy, likely through clinical evaluation or self-reported health.
- For sensitivity, the ground truth was derived from "an autoimmune diseases population." This implies individuals with a clinical diagnosis of an autoimmune disease.
- The document implies that the ground truth for these populations was established through standard clinical diagnostic practices, rather than a specific expert consensus for this study.
-
The sample size for the training set:
- This information is not applicable as this is not a machine learning or AI device that requires a "training set." The device is a chemical/biological assay.
-
How the ground truth for the training set was established:
- This information is not applicable as this is not a machine learning or AI device.
{0}------------------------------------------------
RhiGene an MBL Compa
RhiGene Inc 55 State Street Suite 104 es Plaines, IL 60016 TEL : 847-375-9091 800-447-0781 FAX : 847-375-9093
NOV 19 2004
SUMMARY OF 510(K) SAFETY AND EFFECTIVENESS HEP-ANAN Test System September 10, 2004
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The HEP-ANA Test system is compared to a legally marketed predicate device and a substantial equivalence claim made. The predicate device is RhiGene Titer-Fluor ANA Test System (manufactured by BION ENTERPRISES, Des Plaines, IL, K872845), currently marketed by RhiGene. Inc. Des Plaines, IL,
The RhiGene HEP-ANA Test System is an indirect fluorescent antibody assay utilizing HEp-2 tissue culture cells as a substrate, similar to the predicate device. Diluted serum samples are incubated on substrate slides coated with HEP-2 (human epithelial) cells. Incubation allows the anti-nuclear antibodies (ANA) present in the samples to react with the antigen. After the removal of unbound serum proteins by washing, antibodies specific for human immunoglobulins, labeled with fluorescein isothiocyanate (FITC), are added forming complexes with the nuclear bound antibodies. Following another washing step, coverslips are mounted and then the slides are examined with a fluorescence microscope. The total incubation time (at room temperature in a moist chamber) of the assay is 40 minutes.
The intended use of the device is a qualitative and/or semi-quantitative indirect fluorescent antibody assay for the determination of antinuclear antibodies in human serum. The HEP-ANA Test System is intended for in vitro diagnostic use as an aid in the determination of certain autoimmune diseases.
Performance indicates that HEP-ANA Test system and the RhiGene Titer-Fluor ANA Test System are equivalent. In-house studies indicate a clinical specificity of 82% and 78% for ANA in a healthy donor serum population respectively. Additional studies resulted a sensitivity of 75% with an autoimmune diseases population on both assav. In general, the performance characteristics are comparable between the two methods. These results are also in compliance with those in published literature for ANA detection. The clinical studies performed demonstrate that the HEP-ANA test system is safe and effective.
Yuush Role
9/15/2004
Date
Yusuke Kobe Vice President, Sales and Marketing Department
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of a human figure embracing or protecting another, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular fashion around the emblem. The emblem is black and white.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Corgenix, Inc. c/o Mr. Yusuke Kobe Vice President Rhigene. Inc. 455 State Street Des Plaines, IL 60016
NOV 1 9 2004
一
Re: K042680
Trade/Device Name: RhiGene Hep-ANA Test System Regulation Number: 21 CFR 866.5100 Regulation Name: Antinuclear Antibody, Immunological Test System Regulatory Class: Class II Product Code: DHN Dated: September 14, 2004 Received: September 29, 2004
Dear Mr Kobe:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{2}------------------------------------------------
Page 2 -- Mr. Yusuke Kobe
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to legally premated predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address
http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Robert Zeday
Robert L. Becker, Jr., M.D. PhD Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use
510(k) Number (if known); K 042680
RhiGene HEP-ANA Test Syotem Device Namé:
Indications For Use:
The HEP-ANA Test System is an indirect fluorescent antibody assay utilizing HEp-2 tissue culture cells as a substrate for the qualitative and/or semi-quantitative determination of antinuclear antibodies in human serum. The HEP-ANA Test System is intended for use as an aid in the diagnosis of certain autoimument diseases.
The HEP-ANA Test System is intended to be used by clinical (hospital and reference) laboratories.
Prescription Use _ X
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Mana Chan
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
Page 1 of ________
510(k) K042680
§ 866.5100 Antinuclear antibody immunological test system.
(a)
Identification. An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).(b)
Classification. Class II (performance standards).